**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78119

**Manuscript Type:** CASE REPORT

**Favorable response after radiation therapy for intraductal papillary mucinous neoplasms manifesting as acute recurrent pancreatitis: A case report**

Harigai A *et al*. Radiotherapy for IPMN causing AP

Ayaka Harigai, Kiyoshi Kume, Noriyoshi Takahashi, So Omata, Rei Umezawa, Keiichi Jingu, Atsushi Masamune

**Ayaka Harigai, Noriyoshi Takahashi, So Omata, Rei Umezawa, Keiichi Jingu,** Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

**Kiyoshi Kume, Atsushi Masamune,** Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

**Author contributions:** Harigai A, Takahashi N and Umezawa R reviewed the literature; Kume K and Umezawa R followed this case on outpatient department; Omata S and Umezawa R contributed to radiation therapy treatment planning; Harigai A, Kume K, Umezawa R, Jingu K and Masamune A contributed to manuscript drafting; and all authors issued final approval for the version to be submitted.

**Corresponding author: Ayaka Harigai, MD,** Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. ayaka.harigai.e6@tohoku.ac.jp

**Received:** June 17, 2022

**Revised:** August 17, 2022

**Accepted:** September 7, 2022

**Published online:** October 26, 2022

**Abstract**

BACKGROUND

There has been an increasing number of elderly patients with intraductal papillary mucinous neoplasm (IPMN), who are surgically intolerant and require less invasive treatment options, which are limited. In the present study, we report a case of IPMN presenting with acute recurrent pancreatitis (ARP), in which radiation therapy effectively prevented further attacks of ARP and reduced tumor volume.

CASE SUMMARY

An 83-year-old man was referred to our hospital with an asymptomatic incidental pancreatic cyst. Endoscopic ultrasound imaging and magnetic resonance cholangiopancreatography revealed a multiloculated tumor in the head of the pancreas, with dilated pancreatic ducts and mural nodules. The patient was diagnosed with mixed-type IPMN, and five years later, he developed ARP. Several endoscopic pancreatic ductal balloon dilatations failed to prevent further ARP attacks. Surgery was considered clinically inappropriate because of his old age and comorbidities. He was referred to our department for radiation therapy targeted at those lesions causing intraductal hypertension and radiation was administered at a dose of 50 Gy. An magnetic resonance imaging scan taken ten weeks after treatment revealed a decrease in tumor size and improvement of pancreatic duct dilatation. Fourteen months later, he remains symptom-free from ARP.

CONCLUSION

This case highlights the important role of radiation therapy in mitigating the signs and symptoms of ARP in patients with inoperable IPMN.

**Key Words:** Intraductal papillary mucinous neoplasm; Acute recurrent pancreatitis; Pancreas; Radiation therapy; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Harigai A, Kume K, Takahashi N, Omata S, Umezawa R, Jingu K, Masamune A. Favorable response after radiation therapy for intraductal papillary mucinous neoplasms manifesting as acute recurrent pancreatitis: A case report. *World J Clin Cases* 2022; 10(30): 11116-11121

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i30/11116.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i30.11116

**Core Tip:** For intraductal papillary mucinous neoplasm (IPMN) patients with symptoms of acute recurrent pancreatitis (ARP), the only therapeutic option recommended by current guidelines is surgical intervention. However, a growing number of IPMN patients require minimally invasive treatment options because of old age, systemic conditions, or personal preference. Herein, we present a case of IPMN presenting with ARP, in which radiation therapy effectively prevented further attacks of ARP and reduced tumor volume. This case highlights the important role of radiation therapy in preventing further episodes of ARP in patients with IPMN who cannot undergo surgery.

**INTRODUCTION**

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a cystic lesion in which mucin-producing neoplastic epithelia proliferate abnormally. IPMN is benign, but is known to have malignant potential and requires regular surveillance; surgical resection is recommended for lesions at a high risk of malignancy. High-resolution imaging technology is being increasingly used to diagnose IPMN before it manifests any signs or symptoms[1]. Most patients with IPMN are asymptomatic until malignant transformation and are eventually diagnosed with intraductal papillary mucinous cancer, which has a poor prognosis. Therefore, current efforts are focused on identifying and treating IPMNs that are at a high risk of malignancy.

Recent studies have reported that some IPMNs present with acute pancreatitis (AP) or acute recurrent pancreatitis (ARP) associated with intraductal hypertension[2]. The prevention of repetitive attacks of ARP is preferred because ARP reduces the patients’ quality of life and may lead to irreversible chronic pancreatitis[3]. The latest guidelines state that patients with IPMN and accompanying AP may undergo surgical resection for symptomatic relief[4]. However, there has been inadequate discussion regarding other treatment options when surgery is not clinically appropriate. Here, we report a case of IPMN with ARP in which radiation therapy successfully prevented further attacks of ARP and reduced the tumor volume.

**CASE PRESENTATION**

***Chief complaints***

An 83-year-old man diagnosed with IPMN was referred to our radiation oncology department because of repetitive episodes of ARP resistant to endoscopic treatment.

***History of present illness***

The patient visited a physician to investigate an incidentally detected asymptomatic pancreatic cyst, and was subsequently referred to our hospital for suspected IPMN. Endoscopic ultrasound (EUS) imaging and magnetic resonance cholangiopancreatography (MRCP) revealed a 30 mm multiloculated tumor, located in the head of the pancreas; the main duct had a diameter of 10 mm and the mural nodules were 8 mm in height. The patient was diagnosed with mixed-type IPMN (Figure 1).

The patient was regularly monitored for four years using imaging for signs of malignancy. During regular outpatient surveillance, gradual dilation of the main pancreatic duct to 13 mm was observed, which met the “high-risk stigmata” criteria for surgical resection, as per IPMN management guidelines[4-6]. The patient’s old age and personal preference were indicative of conservative management with follow-up and not surgical intervention. Five years after the initial diagnosis, he developed mild AP twice, but recovered with supportive measures. However, the following year, he developed ARP once a month for three consecutive months. Several attempts at endoscopic pancreatic ductal balloon dilatation failed to prevent the recurrence of AP, and pancreatic juice samples obtained by these endoscopic procedures did not show cytological malignancy. Although international IPMN guidelines suggest surgery for symptomatic relief in pancreatitis[4], the surgeons who consulted with this patient concluded that pancreaticoduodenectomy would not be clinically appropriate because of his old age and comorbidities. Because the episodes of ARP in this case were mainly attributed to intraductal hypertension caused by viscous mucin-rich pancreatic juice secreted from IPMN, the patient was referred to our department for radiation therapy to reduce mucin secretion and prevent further episodes of AP.

***History of past illness***

The patient had a medical history of right lacunar infarction with residual hemiparesis, prostate cancer, colorectal polyps, nephrotic syndrome, chronic pulmonary obstructive disease, and hemorrhoids.

***Personal and family history***

He had smoked 60 cigarettes per day for 55 years, from 22 to 77 years of age.

***Physical examination***

On presentation to our outpatient clinic, the patient had no abnormal pathological signs or symptoms, including jaundice.

***Laboratory examinations***

At our radiation oncology department, laboratory tests indicated that complete blood count, C-reactive protein, liver enzymes, and pancreatic enzymes, were within the normal range.

***Imaging examinations***

One month before initiating radiation therapy, MRCP revealed a 36.5 mm multiloculated tumor in the head of the pancreas and significant pancreatic main duct dilatation (17 mm in diameter). The common bile duct was not dilated (Figure 2).

**FINAL DIAGNOSIS**

The final diagnosis in the current case was IPMN leading to episodes of ARP, which was not indicated for surgery due to the patient’s age and comorbidities.

**TREATMENT**

The patient was treated with radiation therapy at a total dose of 50 Gy in 25 fractions for 5 wk. Radiation therapy was delivered using 10 MV photon beams from a linear accelerator equipped with a multileaf collimator. Volumetric modulated arc therapy was performed to reduce acute gastrointestinal toxicity (Figure 3). The gross target volume (GTV) was defined as the IPMN lesion, and the clinical target volume (CTV) was defined as equal to the GTV. The internal target volume for GTV was contoured with reference to the respiratory movement, using four-dimensional computed tomography. The planning target volume (PTV) was defined as the CTV plus a 5 mm margin. The prescribed dose was calculated to cover 95% of the PTV.

**OUTCOME AND FOLLOW-UP**

During radiation therapy, the patient reported symptoms of acute radiation toxicity such as fatigue, nausea, radiation dermatitis, and diarrhea, all of which corresponded to grades 1 and 2 of the Common Terminology Criteria for Adverse Events[7]. The patient recovered completely within six weeks after radiation therapy. Magnetic resonance imaging performed ten weeks after the initiation of radiation therapy revealed a decrease in tumor size from 36 mm to 28 mm and an improvement in pancreatic duct dilatation (Figure 2). The patient had not experienced any symptoms indicating a recurrence of AP until his last follow-up, 14 mo after the administration of radiation therapy.

**DISCUSSION**

To the best of our knowledge, this report presents the first case in which radiation therapy was successfully administered to a patient with repetitive episodes of ARP caused by IPMN. The patient did not report any abdominal symptoms indicative of pancreatitis for at least one year after the completion of radiation therapy. Although chemoradiotherapy has recently been recognized as an adjuvant therapy, performed after surgical resection in patients with IPMN[8], little is known about the role of radiation therapy in unresected IPMN. Kameyama *et al*[9] reported the case of a patient with unresectable IPMNs with suspected involvement of the superior mesenteric artery, in which chemoradiotherapy successfully shrunk the tumor prior to conversion surgery. However, there have been no reports of patients with IPMN receiving radiation therapy for symptomatic relief of ARP. Jang *et al*[2] reported that among 488 patients with IPMN, 34 (7%) developed AP or ARP attributable solely to IPMN. Thus, considering our aging society, our patient is a representative case of ARP caused by IPMN, for which minimally invasive therapeutic measures are preferred. We expect that the number of similar cases will increase in the near future.

Therapeutic measures for ARP attributable to IPMN have not yet been established. Only a short explanatory note on symptomatic IPMN is found at the bottom of the IPMN management algorithm in the international guidelines of IPMN, stating, “pancreatitis may be an indication for surgery for relief of symptoms”[5]. However, regardless of the type of procedure, pancreatic surgery can lead to severe complications including postoperative pancreatic fistula (POPF). POPF, which causes leakage of pancreatic juice, intraperitoneal abscesses, and lethal hemorrhage from pseudoaneurysms, has an incidence of > 10%. Patients who develop ARP due to IPMN can also be treated endoscopically, which unfortunately failed in the present case. Another previously reported treatment option for pancreatic cysts is the injection of ethanol and paclitaxel into the cystic lesion[10]. This EUS-guided technique is undoubtedly less invasive than surgery but could potentially lead to severe complications in patients with IPMN. Because IPMN cysts directly communicate with the main pancreatic duct, post-procedural AP may occur more frequently in IPMN than in other pancreatic cystic lesions[11].

Immediately after the patient was referred to our radiation oncology department, we developed this treatment strategy by hypothesizing that an appropriate dose of radiation therapy could have an effect on abnormal mucin secretion from IPMN. Although chemoradiotherapy might have a better tumor control[9], it was not selected considering the negative cytological malignancy of the pancreatic juice, age, and comorbidities of the patient. Research on adverse late effects of radiation therapy on the pancreas has shown that pancreatic exocrine insufficiency, which could result in malabsorption, occurs at 45 Gy[12]. Recently, there was a case report describing the application of chemoradiotherapy (50.4 Gy irradiation and gemcitabine) for invasive pancreatic IPMN[13]. We set the radiation dose for this patient based on previously reported experiences. We believe that this case will help establish radiation therapy as a novel nonsurgical treatment for patients with ARP caused by IPMN. Therefore, more such cases are essential to investigate the necessary and adequate radiation dose and to establish this treatment strategy.

**CONCLUSION**

This case showed the important role of radiation therapy in recurrent episodes of ARP in patients with IPMN, who cannot undergo surgical resection.

**ACKNOWLEDGEMENTS**

The authors thank the staff of the Department of Radiation Oncology at Tohoku University Hospital for their support in this study.

**REFERENCES**

1 **Klibansky DA**, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. *Clin Gastroenterol Hepatol* 2012; **10**: 555-558 [PMID: 22210438 DOI: 10.1016/j.cgh.2011.12.029]

2 **Jang JW**, Kim MH, Jeong SU, Kim J, Park DH, Lee SS, Seo DW, Lee SK, Kim JH. Clinical characteristics of intraductal papillary mucinous neoplasm manifesting as acute pancreatitis or acute recurrent pancreatitis. *J Gastroenterol Hepatol* 2013; **28**: 731-738 [PMID: 23301513 DOI: 10.1111/jgh.12121]

3 **Braganza JM**, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. *Lancet* 2011; **377**: 1184-1197 [PMID: 21397320 DOI: 10.1016/S0140-6736(10)61852-1]

4 **Tanaka M**, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology* 2017; **17**: 738-753 [PMID: 28735806 DOI: 10.1016/j.pan.2017.07.007]

5 **Tanaka M**, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology* 2012; **12**: 183-197 [PMID: 22687371 DOI: 10.1016/j.pan.2012.04.004]

6 **Tanaka M**. International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas. *Ann Transl Med* 2015; **3**: 286 [PMID: 26697446 DOI: 10.3978/j.issn.2305-5839.2015.11.09]

7 **U.S. Department of Health and Human Services**. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [cited 10 May 2022]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic\_applications/docs/CTCAE\_v5\_Quick\_Reference\_8.5x11.pdf

8 **McMillan MT**, Lewis RS, Drebin JA, Teitelbaum UR, Lee MK, Roses RE, Fraker DL, Vollmer CM. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). *Cancer* 2016; **122**: 521-533 [PMID: 26587698 DOI: 10.1002/cncr.29803]

9 **Kameyama S**, Motonari H, Ishimine T, Isa T. Successful treatment with conversion surgery following chemoradiotherapy for unresectable invasive intraductal papillary mucinous neoplasm. *Clin J Gastroenterol* 2020; **13**: 579-584 [PMID: 31919675 DOI: 10.1007/s12328-019-01086-3]

10 **Seo DW**. EUS-Guided Antitumor Therapy for Pancreatic Tumors. *Gut Liver* 2010; **4** Suppl 1: S76-S81 [PMID: 21103299 DOI: 10.5009/gnl.2010.4.S1.S76]

11 **Choi JH**, Lee SH, Choi YH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT. Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients. *Hepatobiliary Pancreat Dis Int* 2019; **18**: 562-568 [PMID: 31551143 DOI: 10.1016/j.hbpd.2019.09.004]

12 **Russo S**, Ove R, Fajardo L, Tepper J. Adverse Late Effects of Radiation Treatment in the Pancreas. In: Rubin P, Constine L, Marks L. ALERT • Adverse Late Effects of Cancer Treatment. Medical Radiology. Heidelberg: Springer, 2014

13 **Ochiai T**, Igari K, Furuyama T, Ito H, Mitsunori Y, Aihara A, Kumagai Y, Iida M, Odajima H, Tanaka S, Arii S, Yamazaki S. Favorable response after gemcitabine-radiotherapy for invasive pancreatic intraductal papillary mucinous neoplasm: a case report. *Int Surg* 2013; **98**: 340-345 [PMID: 24229021 DOI: 10.9738/INTSURG-D-13-00031.1]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 17, 2022

**First decision:** August 1, 2022

**Article in press:** September 7, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Beji H, Tunisia; Khalil MTASH, Egypt **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ


**Figure Legends**



**Figure 1 Pancreas magnetic resonance imaging scan at referral 5 years ago.** A: Axial T2-weighted imaging (T2WI) image shows a multilobular tumor in the head of pancreas (arrow head); B: T2WI image shows pancreatic duct dilatation (arrow head); C: Magnetic resonance cholangiopancreatography shows a multilobular tumor (arrow head) and pancreatic duct dilatation (arrow).



**Figure 2 Pancreatic magnetic resonance imaging scans of pre- and post-radiation therapy.** A-C: T2-weighted imaging single scans and magnetic resonance cholangiopancreatography (MRCP) taken one month before radiation therapy; D-F: Magnetic resonance imaging scans and MRCP taken three months after radiation therapy. T2WI: T2-weighted imaging; MRCP: Magnetic resonance cholangiopancreatography.



**Figure 3 Computed tomography image with dose distribution of radiation therapy.** A: An axial image; B: A coronal image. White, red, inner-orange, outer-orange and yellow lines show 52.5 Gy, 50 Gy, 47.5 Gy, 45 Gy and 42.5 Gy, respectively.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**